Literature DB >> 17024868

Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy.

M Steven Piver1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17024868

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  10 in total

1.  Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer.

Authors:  Qingqing Lin; Wenchao Liu; Song Xu; Liping Sun
Journal:  Arch Gynecol Obstet       Date:  2021-08-28       Impact factor: 2.344

Review 2.  The Role of Cancer-Associated Fibroblasts in Ovarian Cancer.

Authors:  Mo Zhang; Zhixian Chen; Yan Wang; Hongbo Zhao; Yan Du
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

3.  First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Authors:  Åke Berglund; Anders Ullén; Alla Lisyanskaya; Sergey Orlov; Hans Hagberg; Bengt Tholander; Rolf Lewensohn; Peter Nygren; Jack Spira; Johan Harmenberg; Markus Jerling; Carina Alvfors; Magnus Ringbom; Eva Nordström; Karin Söderlind; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2015-11-10       Impact factor: 3.850

4.  The Role of CCL20-CCR6 Axis in Ovarian Cancer Metastasis.

Authors:  Wan Liu; Wenjing Wang; Ning Zhang; Wen Di
Journal:  Onco Targets Ther       Date:  2020-12-11       Impact factor: 4.147

5.  Identification of MEG8/miR-378d/SOBP axis as a novel regulatory network and associated with immune infiltrates in ovarian carcinoma by integrated bioinformatics analysis.

Authors:  Jian Lei; Zhen-Yu He; Jun Wang; Min Hu; Ping Zhou; Chen-Lu Lian; Li Hua; San-Gang Wu; Juan Zhou
Journal:  Cancer Med       Date:  2021-03-19       Impact factor: 4.452

6.  EIF5A2 enhances stemness of epithelial ovarian cancer cells via a E2F1/KLF4 axis.

Authors:  Kun Wang; Yiyang Wang; Yuanjian Wang; Shujie Liu; Chunyan Wang; Shuo Zhang; Tianli Zhang; Xingsheng Yang
Journal:  Stem Cell Res Ther       Date:  2021-03-16       Impact factor: 6.832

7.  Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer.

Authors:  Feikai Lin; Xiaoduan Li; Xinjing Wang; Huizhen Sun; Ziliang Wang; Xipeng Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-04-07

8.  The role of computed tomography in the assessment of tumour extent and the risk of residual disease after upfront surgery in advanced ovarian cancer (AOC).

Authors:  Mihaela Asp; Susanne Malander; Nils-Olof Wallengren; Sonja Pudaric; Johan Bengtsson; Hanna Sartor; Päivi Kannisto
Journal:  Arch Gynecol Obstet       Date:  2022-03-02       Impact factor: 2.493

9.  Preclinical activity of melflufen (J1) in ovarian cancer.

Authors:  Charlotte Carlier; Sara Strese; Kristina Viktorsson; Ebba Velander; Peter Nygren; Maria Uustalu; Therese Juntti; Rolf Lewensohn; Rolf Larsson; Jack Spira; Elly De Vlieghere; Wim P Ceelen; Joachim Gullbo
Journal:  Oncotarget       Date:  2016-09-13

10.  Hedgehog-Gli2 Signaling Promotes Chemoresistance in Ovarian Cancer Cells by Regulating MDR1.

Authors:  Qian Wang; Xin Wei; Lanyan Hu; Lingling Zhuang; Hong Zhang; Qi Chen
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.